By: Benzinga
UPDATE: KeyBanc Upgrades BioMed Realty Trust to Buy on Lease-Up and Accretive Acquisitions
KeyBanc upgraded BioMed Realty Trust (NYSE: BMR ) from Hold to Buy and announced a $24.00 price target. KeyBanc commented, "Following strong execution on the leasing front, a pipeline of accretive investment activity and a reloading of the balance sheet, we are upgrading shares of BioMed Realty Trust (BMR-NYSE) to
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here